Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Diastolic Heart Failure, Hypertensive Heart Disease
Interventions: DASH/sodium-restricted diet (DASH/SRD), Control Diet; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension, Primary Care
Interventions: Provider nudge, Patient nudge, Pharmacist Virtual Visit; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions: Riociguat, Placebo, Pulmonary endarterectomy; Drug · Procedure
Lead sponsor: International CTEPH Association; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Sleep Apnea Syndromes
Interventions: Continuous positive airway pressure; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 70 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
Interventions: High-Touch, High-Tech, Optimal Discharge Planning; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Hypertension, Eclampsia, Gestational Hypertension, Cardiovascular Diseases, Toxemia, Pregnancy Complications, Vascular Diseases, Hypertension, Pregnancy Induced, Hypertension;Pre-Eclamptic
Interventions: Usual care, Tight blood pressure control; Drug
Lead sponsor: Alisse Hauspurg; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax, Vascular Diseases
Interventions: Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS); Device · Procedure
Lead sponsor: Argon Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • New York, New York • Chapel Hill, North Carolina

Conditions: Open Angle Glaucoma (OAG), Glaucoma
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Gestational Diabetes, Gestational Hypertension, High Risk Pregnancy, Preeclampsia
Interventions: Maternal Health Management Program; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension, Dyslipidemia, Diabetes Mellitus, Obesity, Cardiovascular Disease
Interventions: Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants, Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 64 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: Farmington, Connecticut • Hartford, Connecticut • Storrs, Connecticut

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: AL-37807; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Hypertension
Interventions: Atkins diet (low carbohydrate diet), DASH diet (high carbohydrate diet); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension
Interventions: Walk Together, Hypertension education; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ischemic Stroke, Hypertension, Hyperlipidemias, Diabetes
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Elevated Blood Pressure, Hypertension
Interventions: Boxing Training, Control flexibility; Other
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury, Pulmonary Arterial Hypertension, Cardiovascular Diseases
Interventions: [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging; Drug · Diagnostic Test
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma, Open-Angle, Cataract
Interventions: Vivity IOL; Device
Lead sponsor: Vold Vision P.L.L.C; Other
Eligibility: 45 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Hypertension
Interventions: CTX340, Placebo; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions: 6R-BH4, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma
Interventions: iStent Inject (GTS400), Cataract Surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 22
States / cities: Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more

Conditions: Glaucoma, Intraocular Pressure
Interventions: Nanodropper; Device
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Hypertension, Circadian Dysregulation, Salt; Excess
Interventions: Oral sodium supplementation; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years to 45 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)

Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

Race And CPAP Effectiveness

Integrated Care (IC) Models for Patient-Centered Outcomes

Optimal Blood Pressure Treatment Thresholds Postpartum

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

Preventing Obstetric Complications With Dietary Intervention

A Novel Digital Tool Clinicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

Effectiveness of a Low Carbohydrate Diet Versus a High Carbohydrate Diet in Promoting Weight Loss and Improved Health

Walk Together Efficacy Trial

Imaging the Pathogenesis of Cerebral Small Vessel Disease

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

Clinical Effectiveness of Boxing Training in Individuals With Elevated Blood Pressure or Stage 1 Hypertension

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

Glaucoma Drop Aids Part 2

Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans